Court Tosses Suit Over Lundbeck's Purchase Of Two Drugs Used In Premature Infants
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal judge finds NeoProfen and Indocin IV are not in the same product market; FTC and Minnesota filed suit after Lundbeck raised the price of Indocin, then the only approved drug, by 1,300%.